|

PD-L1 inhibitor Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University Cancer Hospital & Institute1
  • Eastern Hepatobiliary Surgery Hospital1

Indications

  • Cancer2
  • ICC1
  • Limited-stage Small Cell Lung Cancer (LS-SCLC)1
  • Advanced Cancer1
  • Lung Cancer1

Other2 trials

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC
Phase 2
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.